Updated: 19 hours ago
In a phase III trial published in 2026, women with previously treated HER2-positive metastatic breast cancer who received a Chinese-developed drug, trastuzumab rezetecan, went a median of 30.6 months before their cancer progressed — versus 8.3 months on the comparison treatment (ASCO Post, Aug 2026). That is one of the largest gains reported in this setting.
Results like this are why international patients are looking at breast cancer treatment in China. China diagnoses about 357,000 new breast cancer cases a year (Chinese Medical Journal, 2024), and that scale supports large, fast trials of Chinese-developed drugs.
The short answer: China has several breast cancer drugs approved there that may not yet be available where you live, especially antibody-drug conjugates (ADCs) and targeted pills. Whether any helps you depends on your breast cancer subtype — HER2-positive, hormone receptor (HR)-positive, or triple-negative — and what treatments you've already had.
Key Takeaways |
|
Table of Contents
Why Your Breast Cancer Subtype Decides Your Options
Breast cancer is not one disease. Pathologists test the tumor for estrogen and progesterone receptors (HR) and HER2. The results place it in one of three main groups, and each group responds to different drugs.
The tests discussed here are specific to breast cancer. For comparison, see how lung cancer biomarkers guide treatment.
Your subtype can change over time. A recurrence can test differently from the original tumor, so doctors often recommend a new biopsy of the metastasis before choosing treatment. This matters for every option below.
HER2-Positive Breast Cancer: Two Chinese Advances
A new ADC: trastuzumab rezetecan (HORIZON-Breast01). ADCs are antibodies that carry chemotherapy directly to cancer cells. In the HORIZON-Breast01 phase III trial, led by Prof. Erwei Song at Sun Yat-sen Memorial Hospital, Sun Yat-sen University (Guangzhou), 287 women previously treated with trastuzumab and a taxane received trastuzumab rezetecan or pyrotinib plus capecitabine. Median progression-free survival was 30.6 vs. 8.3 months (HR 0.22), and 12-month survival was 96.3% vs. 88.4% (ASCO Post, Aug 2026; Lancet Oncology).
Limitations: overall survival data are still immature. Serious side effects were common in both arms (70% vs. 63%), and 3% developed interstitial lung disease, a known ADC risk. The comparator was pyrotinib-based, not trastuzumab deruxtecan (Enhertu), the main ADC used internationally, so this trial doesn't show it beats Enhertu.
A Chinese targeted pill: pyrotinib (PHOEBE). In the PHOEBE phase III trial, led by Prof. Binghe Xu at the National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences (Beijing), pyrotinib plus capecitabine was compared with lapatinib plus capecitabine in 266 women. Median overall survival was 39.4 vs. 28.6 months (HealthDay via Drugs.com, Nov 2023). The trial was funded by pyrotinib's developer, Jiangsu Hengrui.
HR-Positive, HER2-Negative Breast Cancer: A Chinese CDK4/6 Inhibitor
This is the most common subtype. Treatment usually combines hormone therapy with a CDK4/6 inhibitor, such as palbociclib or ribociclib.
Dalpiciclib (DAWNA-1) is a Chinese-developed CDK4/6 inhibitor. In the DAWNA-1 phase III trial, also led by Prof. Binghe Xu, 361 women whose cancer had progressed on hormone therapy received fulvestrant with dalpiciclib or placebo. Median progression-free survival was 15.7 vs. 7.2 months (HR 0.42) (Pharmacy Times; Nature Medicine, 2021). Severe drops in white blood cells were very common (84% grade 3+ neutropenia), though serious complications were rare.
What this means for you: dalpiciclib is a new option in the same drug class, not a different kind of treatment. If you already have access to palbociclib or ribociclib, there's no evidence that dalpiciclib is better, because it was compared with placebo.
Triple-Negative Breast Cancer: New Options After Chemotherapy
Triple-negative breast cancer (TNBC) lacks HR and HER2, so it has fewer targeted options.
A TROP2-targeted ADC: sacituzumab tirumotecan (OptiTROP-Breast01). In this phase III trial, again led by Prof. Binghe Xu, 263 patients who had received at least two prior chemotherapies got sacituzumab tirumotecan or standard chemotherapy. Median progression-free survival was 5.7 vs. 2.3 months, and median overall survival had not been reached versus 9.4 months at interim analysis (ASCO Post, July 2024). It was approved in China in November 2024 for this use (OncLive, Nov 2024). Its developer, Kelun-Biotech, partners with Merck (MSD) internationally.
Precision subtyping (FUTURE trial). At Fudan University Shanghai Cancer Center, Prof. Zhi-Ming Shao's team split TNBC into molecular subgroups and matched each to a targeted drug or immunotherapy. In 141 heavily pretreated patients, 29.8% saw significant tumor shrinkage (Cell Research, 2023). This is research, not routine care, but it reflects how FUSCC approaches TNBC.
Preventing Recurrence or Out of Options: Personalized Vaccines and Cell Therapy
Two groups of patients ask most often about vaccines and cell therapy: women with high-risk early breast cancer who want to lower the chance of recurrence after surgery, and women whose metastatic cancer has progressed after standard treatments. For breast cancer, all of these approaches are still investigational, in China and elsewhere.
Personalized cancer vaccines to prevent recurrence. These vaccines are built from mutations (neoantigens) found in a patient's own tumor and aim to train the immune system to catch any cancer cells left after treatment. The most-cited data come from an international first-in-human study published in Nature: in 14 women with early-stage triple-negative breast cancer, an individualized mRNA vaccine triggered immune responses in all 14, and 11 remained relapse-free after a median of about five years (News-Medical, Feb 2026; Nature). With no control group and only 14 patients, it cannot show the vaccine prevented relapse. In China, personalized mRNA vaccines are being given in research and special-access settings: at West China Lecheng Hospital in Hainan's Boao Lecheng zone, for example, a patient with early-stage lung cancer received a personalized mRNA vaccine intended to lower relapse risk (SCMP).
DC vaccines. Dendritic cell vaccines load a patient's own immune cells with tumor antigens. Fudan University Shanghai Cancer Center is running a small registered study of a personalized neoantigen DC vaccine for advanced solid tumors, about 9 participants, recruiting through 2026 (CenterWatch, NCT06682117). Its listing focuses on head and neck, lung and esophageal cancers, not breast cancer, and there are no published results yet.
TIL therapy when out of options. TIL therapy grows immune cells from a patient's own tumor and infuses them back in large numbers. A Chinese TIL product, GC101 (Shanghai Juncell Therapeutics), is in an early phase 1 trial specifically for advanced breast cancer, with about 50 patients planned and completion expected around 2026–2027 (NCT05142475). No breast cancer results have been published. TIL treatment requires surgery to collect tumor tissue, chemotherapy to prepare the body, and a hospital stay, so it suits only patients in reasonably good health.
What this means for you: these are options to ask about, not to plan around. They may be worth exploring if you have high-risk early disease and want to know about trials, or if approved treatments have stopped working. Eligibility is narrow, places are limited, and not every program accepts international patients. Hainan's Boao Lecheng zone may offer some therapies approved overseas, but availability must be confirmed case by case.
Hospitals and Specialists Behind These Advances
The hospitals below are listed because they led one of the trials above, not as a general ranking.
National Cancer Center / Cancer Hospital, CAMS
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Fudan University Shanghai Cancer Center
Specialists Behind the Research
Photos and profiles: CAMS, Sun Yat-sen University and FUSCC. The Sun Yat-sen Memorial Hospital image shows its South Campus Yixian Building in a 2015 university report. Confirm current appointments and international-patient access directly.
China's Breast Cancer Options at a Glance
Boao Lecheng: Hainan's Boao Lecheng medical zone can also provide some drugs approved overseas but not yet in mainland China, with more than 500 such drugs and devices introduced (Xinhua, Jan 2026). This is mainly useful when an internationally approved drug isn't available in your own country.
How Much Does Breast Cancer Treatment in China Cost?
ChinaCureLink's general planning range for solid tumor treatment, including breast cancer, is US$20,000–$50,000. This is an internal budget estimate, not a hospital quote or a verified average for breast cancer. Your actual cost depends on your diagnosis, treatment plan, drug cycles and length of stay. The table also shows the separate general range for advanced blood cancer treatment for context.
What a hospital quote usually covers: treatment, medicines given in hospital, scans and tests during treatment, and your inpatient stay. What it often leaves out: take-home drugs, treatment of complications, extra cycles if your plan changes, and your travel, hotel and caregiver costs. Always ask for an itemized estimate and what is excluded.
Ways to keep costs predictable:
Get a written estimate before you travel, based on your actual records.
Ask about international patient discounts. When a hospital sends you a quote, ChinaCureLink helps you apply for any international patient discount it offers.
Budget for long-term drugs. Many newer drugs are taken for months. If a drug is approved only in China, plan how you'll pay for and receive refills after you return home.
Check your insurance. Most international health plans don't cover treatment in China, and China's national insurance doesn't cover foreign patients.
What International Breast Cancer Patients Should Know Before Traveling
Many of these drugs are approved only in China. If you start one there, your home oncologist may not be able to prescribe it. Plan how you'll get continued supply and monitoring before you begin.
If you’re arranging care for someone with lung cancer, use the step-by-step lung cancer treatment guide for its records and specialist-review process.
ADCs need careful monitoring. Lung inflammation (interstitial lung disease) and low blood counts can occur. You'll need regular scans and blood tests, ideally coordinated with a doctor at home.
Bring complete pathology. Chinese specialists will want HR and HER2 results (including HER2-low status), recent biopsy reports, and a full treatment history with dates and responses.
Independent Guidance Before You Travel
ChinaCureLink (chinacurelink.com), a Medebound HEALTH company, is an independent medical facilitator and patient advocate helping international patients explore serious disease treatment in the US or in China. It was founded by physicians 10 years ago and has helped around 3,000 international patients.
For breast cancer, the key question is usually whether a China-approved drug offers something your current options don't. ChinaCureLink represents the patient, not any hospital. Its team reviews your pathology and treatment history and matches your case with up to three relevant Chinese hospitals and specialists. Applying and hospital and specialist matching are free. If you want a video second opinion with a Chinese breast cancer specialist before deciding whether to travel, that is a paid consultation, and its fee is confirmed with you before booking.
You Contact the Hospital vs. via ChinaCureLink
Both routes can work. Many large Chinese hospitals have international departments, and some patients go direct. Here is what each route looks like, step by step.
When going direct may be enough: you have lived in China, you can handle records and communication, and you mainly need an appointment. When guided help adds most: you're unsure which treatment or hospital fits, your case is complex or rare, you want a specialist's opinion before deciding to travel, or you prefer to have an on-site medical interpretor and guide.
Your Next Steps
If you’re ready to move from comparing options to arranging a review, see how to get breast cancer treatment in China.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Frequently Asked Questions
Is breast cancer treatment in China better than in the US or Europe?
Standard care at leading centers is broadly similar. China's potential advantage lies in specific drugs approved there , such as trastuzumab rezetecan or sacituzumab tirumotecan, that may not yet be available in your country.
What is the best hospital for breast cancer in China?
It depends on your subtype and situation. The National Cancer Center in Beijing, Sun Yat-sen Memorial Hospital in Guangzhou and Fudan University Shanghai Cancer Center have each led major breast cancer trials.
Can I get these drugs if I've already had Enhertu or other ADCs?
Possibly, but most trials above enrolled patients who had not received those newer drugs. A specialist needs to review your full treatment history to judge whether a Chinese option is likely to help.
What records should I prepare?
Pathology reports with HR, HER2 and Ki-67 results, any genetic tests (such as BRCA or PIK3CA), recent scans, and a dated list of all treatments and responses.
The Bottom Line
China has developed several breast cancer drugs with strong phase III results, especially for HER2-positive and triple-negative disease. Many are approved only in China so far, and most were tested against older treatments, not today's international best options.
The right next step is a specialist review of your subtype and treatment history to see whether any Chinese option adds something real for you.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Sources and Further Reading
ChinaCureLink internal treatment-budget estimates, supplied November 2026: US$20,000–$50,000 for solid tumors; US$80,000+ for advanced blood cancers. Planning ranges, not individual hospital quotes.
Medical Disclaimer
This article provides general information and does not replace individual medical advice. Eligibility, treatment access, risks, fees and follow-up require specialist assessment. Research findings do not guarantee outcomes. Confirm current access directly with the treating hospital before travel.
